TIL Quote, Financials, Valuation and Earnings

Merck & has a net margin of -- compared to Instil Bio's net margin of 18.95%. Instil Bio's return on equity of -- beat Merck &'s return on equity of 29.26%.

Instil Bio has a consensus price target of --, signalling upside risk potential of 358.35%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.44%. Given that Instil Bio has higher upside potential than Merck &, analysts believe Instil Bio is more attractive than Merck &.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Instil Bio pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Instil Bio's net income of -$23M is lower than Merck &'s net income of $3.2B. Notably, Instil Bio's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Instil Bio's net margin of -49.65%. Instil Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Instil Bio has a consensus price target of --, signalling upside risk potential of 358.35%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Instil Bio, analysts believe NovaBay Pharmaceuticals is more attractive than Instil Bio.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Instil Bio's net income of -$23M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Instil Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Instil Bio's net margin of -2357.27%. Instil Bio's return on equity of -- beat Palatin Technologies's return on equity of --.

Instil Bio has a consensus price target of --, signalling upside risk potential of 358.35%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Instil Bio, analysts believe Palatin Technologies is more attractive than Instil Bio.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Instil Bio's net income of -$23M is lower than Palatin Technologies's net income of -$7.8M. Notably, Instil Bio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Instil Bio's net margin of --. Instil Bio's return on equity of -- beat Theriva Biologics's return on equity of --.

Instil Bio has a consensus price target of --, signalling upside risk potential of 358.35%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 5042.05%. Given that Theriva Biologics has higher upside potential than Instil Bio, analysts believe Theriva Biologics is more attractive than Instil Bio.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Instil Bio's net income of -$23M is lower than Theriva Biologics's net income of -$7.7M. Notably, Instil Bio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.